Physician profile
Dina E Linfoot
NPI 1760592927
$11,513.74
in general payments reported to CMS, 2019-2025
29 companies · $236 in 2025
The $236 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,693 · 2020: $2,893 · 2021: $1,560 · 2022: $1,601 · 2023: $148 · 2024: $383 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $767.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $7,108.23 | 2019-2020 | |
| Organon LLC | $2,775.90 | 2021-2025 | Nexplanon |
| Astellas Pharma US INC | $286.76 | 2019-2025 | Veozah |
| Sumitomo Pharma America, INC. | $203.86 | 2023-2024 | Myfembree |
| Abbvie INC. | $192.34 | 2019-2022 | |
| Hologic Sales and Service, LLC | $139.65 | 2019-2025 | Acessa Provu System, Thinprep 2000 Processor, Omni Hysteroscope |
| Therapeuticsmd, INC. | $94.94 | 2019 | |
| Aspira Women'S Health INC | $78.93 | 2021-2022 | |
| Sage Therapeutics, LLC | $69.91 | 2024 | |
| Pfizer INC. | $65.01 | 2022-2025 | |
| Amag Pharmaceuticals, INC. | $54.18 | 2019 | |
| Myovant Sciences INC. | $46.98 | 2022 | |
| Agile Therapeutics, INC. | $35.88 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.12 | 2019 | |
| Boston Scientific Corporation | $33.08 | 2019-2023 | Upsylon |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $32.97 | 2024 | |
| Sanofi Pasteur INC. | $27.65 | 2024 | |
| Lupin INC. | $25.13 | 2019 | |
| Roche Diagnostics Corporation | $24.71 | 2019 | |
| Ethicon US, LLC | $23.02 | 2023 | Vistaseal |
| Exeltis, USA INC. | $21.87 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $21.04 | 2024 | |
| Lilly USA, LLC | $20.30 | 2025 | Mounjaro, Zepbound |
| Lsi Solutions INC | $20.02 | 2025 | Fornisee |
| Allergan, INC. | $18.99 | 2019 | |
| Scynexis, INC. | $16.63 | 2022 | |
| Daiichi Sankyo INC. | $16.09 | 2019 | |
| Minerva Surgical, INC | $13.28 | 2024 | |
| Millicent US INC | $13.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Linfoot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.